Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Roles of Mucosal Immunity against Mycobacterium tuberculosis Infection.

Li W, Deng G, Li M, Liu X, Wang Y.

Tuberc Res Treat. 2012;2012:791728. doi: 10.1155/2012/791728. Epub 2012 Nov 1.

2.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
3.

[Frontier of mycobacterium research--host vs. mycobacterium].

Okada M, Shirakawa T.

Kekkaku. 2005 Sep;80(9):613-29. Japanese.

PMID:
16245793
4.

[Recent progress in mycobacteriology].

Okada M, Kobayashi K.

Kekkaku. 2007 Oct;82(10):783-99. Japanese.

PMID:
18018602
5.

Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis.

Wang J, Thorson L, Stokes RW, Santosuosso M, Huygen K, Zganiacz A, Hitt M, Xing Z.

J Immunol. 2004 Nov 15;173(10):6357-65.

6.

Mucosal immunization against respiratory bacterial pathogens.

Foxwell AR, Kyd JM, Cripps AW.

Expert Rev Vaccines. 2003 Aug;2(4):551-60. Review.

PMID:
14711339
7.

Macrophages and tuberculosis.

Fenton MJ.

Curr Opin Hematol. 1998 Jan;5(1):72-8. Review.

PMID:
9515206
8.

Immunological protection against mycobacterium tuberculosis infection.

Yoshikai Y.

Crit Rev Immunol. 2006;26(6):515-26. Review.

PMID:
17341192
9.
10.

Mucosal responses to parenteral and mucosal vaccines.

Kaul D, Ogra PL.

Dev Biol Stand. 1998;95:141-6. Review.

PMID:
9855424
12.

Innate immunity in the mucosal immune system.

Nochi T, Kiyono H.

Curr Pharm Des. 2006;12(32):4203-13. Review.

PMID:
17100623
13.

Recombinant poxviruses as mucosal vaccine vectors.

Gherardi MM, Esteban M.

J Gen Virol. 2005 Nov;86(Pt 11):2925-36. Review.

PMID:
16227213
14.

Should a new tuberculosis vaccine be administered intranasally?

Källenius G, Pawlowski A, Brandtzaeg P, Svenson S.

Tuberculosis (Edinb). 2007 Jul;87(4):257-66. Epub 2007 Feb 26. Review.

PMID:
17321797
15.

The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis.

Andersen CS, Dietrich J, Agger EM, Lycke NY, Lövgren K, Andersen P.

Infect Immun. 2007 Jan;75(1):408-16. Epub 2006 Oct 30.

16.

[Protective immunity against Mycobacterium tuberculosis].

Kawamura I.

Kekkaku. 2006 Nov;81(11):687-91. Review. Japanese.

PMID:
17154048
17.

Mucosal immunization with recombinant heparin-binding haemagglutinin adhesin suppresses extrapulmonary dissemination of Mycobacterium bovis bacillus Calmette-Guérin (BCG) in infected mice.

Kohama H, Umemura M, Okamoto Y, Yahagi A, Goga H, Harakuni T, Matsuzaki G, Arakawa T.

Vaccine. 2008 Feb 13;26(7):924-32. doi: 10.1016/j.vaccine.2007.12.005. Epub 2007 Dec 26.

PMID:
18192091
19.
20.

New perspectives in vaccine development: mucosal immunity to infections.

McGhee JR, Kiyono H.

Infect Agents Dis. 1993 Apr;2(2):55-73. Review.

PMID:
8162356
Items per page

Supplemental Content

Write to the Help Desk